Casio to Release G-SHOCK with Minimalist Metal Design and Even Better Fit
Reconstructed Shock-Resistant Structure and Streamlined Exterior TOKYO, Oct. 28, 2025 /PRNewswire/ --…
Total Investment of Approx. USD 11.6 Million in TB and NTD R&D Projects With Partners Including Fujifilm, Stop TB Partnership, and the Ohio State University
TOKYO, Oct. 29, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced…
Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease
In Canada, lecanemab is indicated for the treatment of adult patients with…
Updated IOC report shows 86 per cent of all permanent Olympic venues still in use
23 October 2025 - An updated analysis of venues shows that 86 per…
Casio to Release Ring-Sized G-SHOCK
Shock-Resistant Structure and 200-Meter Water Resistance Packed in Smallest Size in Brand's…
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
TOKYO & HAYWARD, Calif.--(BUSINESS WIRE)--Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences,…
ESR and Colt DCS Announce Joint Venture on New Osaka Data Centre Development
TOKYO, Oct. 16, 2025 /PRNewswire/ -- ESR, an Asia-Pacific ("APAC") focused real…
DATROWAY Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to…
Data Eraser Tool “DiskShredder ToGo” Achieves ADISA Product Assurance Certification to NIST 800-88
ADISA’s Research Centre, a UK-based independent test laboratory, certifies its first Japanese…
Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases
Hinge Bio to receive $10 million upfront and is eligible to receive…